Enhanced CXCR4-HRH1 Heteromer Inhibitors and Personalized Cancer Therapy

This inventive concept discloses novel methods and compositions for enhancing the efficacy of CXCR4-HRH1 heteromer inhibitors in cancer treatment, including personalized therapy approaches and optimized inhibitor combinations.

The original patent, 'GPCR heteromer inhibitors and uses thereof', disclosed methods for inhibiting cancer progression using CXCR4-HRH1 heteromer inhibitors. However, the patent's approach had limitations, including the lack of consideration for downstream signaling profiles and heteromer configuration variability. The new inventive concept addresses these limitations by introducing methods for identifying and tailoring inhibitor combinations to specific downstream signaling profiles, thereby enhancing treatment efficacy and personalizing cancer therapy.

The inventive concept comprises four key aspects: 1) identifying cancer cells exhibiting enhanced downstream signaling from CXCR4-HRH1 heteromers; 2) administering tailored combinations of CXCR4 and HRH1 inhibitors based on the specific downstream signaling profile; 3) predicting the responsiveness of cancer cells to CXCR4-HRH1 heteromer inhibitors by measuring calcium mobilization levels; and 4) monitoring treatment efficacy by tracking changes in CXCR4 and HRH1 expression levels. The inventive concept also encompasses a system for personalized cancer therapy, comprising a diagnostic module for detecting CXCR4-HRH1 heteromers and a therapeutic module for administering optimized inhibitor combinations.

The new claims introduce the concept of tailoring inhibitor combinations to specific downstream signaling profiles, which is not disclosed in the original patent. This approach enables personalized cancer therapy and enhances treatment efficacy, thereby providing a novel and non-obvious solution to the limitations of the original patent.

Alternative embodiments of the inventive concept could include using different types of inhibitors, such as small molecules or antibodies, or incorporating additional therapeutic agents to enhance treatment efficacy. Variations of the diagnostic module could include using different detection methods or biomarkers to identify CXCR4-HRH1 heteromers.

The inventive concept has significant commercial potential in the field of personalized cancer therapy, particularly for patients with CXCR4-HRH1 heteromer-positive cancers. The market for targeted cancer therapies is growing rapidly, and this inventive concept could provide a competitive advantage in this space.